753649
Last Update Posted: 2019-11-27
Recruiting has ended
All Genders accepted | 6 Weeks-12 Weeks |
224 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
This study will evaluate GSK Biologicals' DTPa-HBV-IPV/Hib vaccine given as a three-dose primary vaccination course at 2, 4 and 6 months of age, in terms of safety and immunogenicity in different population of infants residing in Canada.
This protocol posting has been updated following Protocol amendment 1 (19-MAY-2010).
Eligibility
Relevant conditions:
Hepatitis B
Tetanus
Poliomyelitis
Diphtheria
Haemophilus Influenzae Type b
Acellular Pertussis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov